Category: Medications - Page 2
Sterile manufacturing for injectables demands extreme cleanliness to prevent life-threatening infections. Learn the key requirements, methods, costs, and real-world failures behind making safe injectable drugs.
Medication Guides are FDA-mandated safety handouts for high-risk prescription drugs. Learn when pharmacists must distribute them, how rules differ by setting, and what’s changing in 2025 to improve patient safety.
Rifampin can drastically reduce the effectiveness of hormonal birth control by speeding up hormone metabolism, leading to breakthrough ovulation and unplanned pregnancy-even with perfect pill use. Learn why only rifampin poses this risk and what to do about it.
Generic drugs cost far less than brand-name drugs not because they're made cheaper, but because labor costs are lower due to scale, outsourcing, and simplified processes. Here's how production labor differs between the two.
Brand manufacturers produce their own generic versions-called authorized generics-to maintain market share after patents expire. These are identical to the brand drug but sold under a different label, often at a higher price than traditional generics.
Australia's PBS makes prescription medicines affordable for millions. Learn how generic drugs, co-payments, and government pricing shape access-and who still falls through the cracks.
Bioavailability studies ensure generic drugs work like brand-name versions by measuring how much of the drug enters your bloodstream. Here’s how the FDA uses AUC and Cmax to approve generics safely and affordably.
ICH guidelines unify global standards for drug safety, reducing redundant testing and speeding up access to safe medicines. Learn how these rules shape every medication you take.
Beta-blockers were once banned for asthma patients due to bronchospasm risks. New research shows cardioselective options like atenolol are safe and effective when used correctly. Learn which ones work and how to use them safely.
The Federal Circuit Court holds exclusive authority over U.S. pharmaceutical patent cases, shaping drug availability, pricing, and innovation. Its rulings on ANDA litigation, dosing patents, and Orange Book listings directly impact generic drug entry and patient access.